Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35060 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Manja Bloem und 20 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Previous studies demonstrated limited efficacy of immune checkpoint inhibitors in unresectable acral melanoma (AM); it remains unclear how this translates to the adjuvant setting. This study investigates clinical outcomes of acral compared to cutaneous melanoma (CM) patients treated with adjuvant anti‐PD‐1 after complete resection. All stages III–IV AM and CM patients receiving adjuvant anti‐PD‐1 after complete resection between 2018 and 2022 were included from the prospective nationwide Dutch Melanoma Treatment Registry. We analyzed recurrence‐free survival (RFS), distant metastasis‐free survival (DMFS), and overall survival (OS). A multivariable Cox regression analysis of RFS was performed to adjust for potential confounders. We included 1958 (86 AM and 1872 CM) patients. At baseline, AM patients more frequently had KIT mutations, higher disease stages, and Eastern Cooperative Oncology Group Performance Status, and fewer BRAF and NRAS mutations. Median RFS was 14.8 months (95% confidence interval [CI]: 11.5–29.3) in AM and 37.4 months (95% CI: 34.6 to not reached) in CM ( p = .002). After correcting for potential confounders, AM remained associated with a higher risk of recurrence (HR adj 1.53; 95% CI: 1.07–2.17; p = .019). Two‐year DMFS tended to be worse for AM than for CM: 64.5% versus 79.7% ( p = .050). Two‐year OS was significantly lower in AM (71.5% vs. 84.3%; p = .027). The results of this study suggest a poorer outcome of adjuvant‐treated AM compared to CM. Studies assessing the added value of adjuvant treatment in AM are needed. Future research should investigate alternative treatment strategies to improve outcomes of high‐risk AM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.
- Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
- Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen, The Netherlands.
ORCID-Profile: Manja Bloem, Olivier J van Not, Melissa M de Meza
Zitieren
APA
Bloem, M., van Not, O. J., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., de Groot, J. B., Haanen, J. B., Hospers, G. A. P., Kapiteijn, E. W., de Meza, M. M., Piersma, D., van Rijn, R. S., Stevense-den Boer, M. A. M., van der Veldt, A. A. M., Vreugdenhil, G., van den Eertwegh, A. J. M., …, & Wouters, M. W. J. M. (2024). Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study. International Journal of Cancer. https://doi.org/10.1002/ijc.35060
Vancouver
Bloem M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, et al. Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study. International Journal of Cancer. 2024. doi:10.1002/ijc.35060
BibTeX
@article{Bloem2024,
author = {Bloem, Manja and van Not, Olivier J and Aarts, Maureen J B and van den Berkmortel, Franchette W P J and Blank, Christian U and Blokx, Willeke A M and Boers-Sonderen, Marye J and Bonenkamp, Johannes J and de Groot, Jan-Willem B and Haanen, John B and Hospers, Geke A P and Kapiteijn, Ellen W and de Meza, Melissa M and Piersma, Djura and van Rijn, Rozemarijn S and Stevense-den Boer, Marion A M and van der Veldt, Astrid A M and Vreugdenhil, Gerard and van den Eertwegh, Alfons J M and Suijkerbuijk, Karijn P M and Wouters, Michel W J M},
title = {Adjuvant treatment with anti‐ PD ‐1 in acral melanoma: A nationwide study},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35060}
}
EUVIMED